Supernus Pharmaceuticals, Inc. has entered into a definitive agreement to acquire US WorldMeds’ CNS portfolio, adding three marketed products in the U.S. and a product candidate in late-stage development.

Products include APOKYN (apomorphine hydrochloride) injection for Parkinson’s disease (PD); MYOBLOC (rimabotulinumtoxinB) injection for the treatment of pain associated with cervical dystonia; XADAGO (safinamide) tablets indicated as an adjunctive treatment for PD episodes; and Apomorphine Infusion Pump, a product candidate for the continuous treatment of motor fluctuations in PD patients. New Drug Application (NDA) submission is expected in 2H20 with potential launch, if approved by the FDA, in 2H21.

“This acquisition aligns extremely well with our strategy of expanding and enhancing our commercial and late-stage assets and is a significant step in strengthening our leadership position in CNS,” said Jack Khattar, President and CEO of Supernus. “We expect this transaction to provide Supernus with enhanced operating cash flow, financial flexibility to execute on our strategy, and a continued strong balance sheet. In addition, the transaction provides increased revenue scale and adds new commercial capabilities that are important for orphan drugs and specialty pharmacy products.”

“The core values of Supernus align very well with US WorldMeds.  We expect a seamless transition with even more patients benefiting from these products under Supernus’ stewardship.  This transaction will allow US WorldMeds to focus on growing our other exciting business units,” commented Paul Breckinridge “Breck” Jones, Sr., Chief Executive Officer of US WorldMeds.